Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer.

被引：0
|
作者：
Osterlind, K
Sánchez, JM
Zatloukal, P
Hamm, J
Belani, CP
Kim, E
Felip, E
Johri, A
Berton, M
Sklenar, I
机构：
[1] Herlev Univ Hosp, DK-2730 Herlev, Denmark
[2] Hosp Germans Trias & Pujol, Barcelona, Spain
[3] Univ Hosp Na Bulovce, Prague, Czech Republic
[4] Norton Healthcare Hosp Inc, Louisville, KY USA
[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[6] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Vall Hebron Univ Hosp, Barcelona, Spain
[8] Novartis Pharmaceut Corp, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：647S / 647S
页数：1
相关论文
共 50 条
  • [1] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer
    Sanchez, J. M.
    Osterlind, K.
    Zatloukal, P.
    Hamm, J.
    Belani, C. P.
    Kim, E.
    Felip, E.
    Berton, M.
    Sklenar, I.
    John, A.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 327 - 327
  • [2] Phase I/II trial of patupilone once every 3 weeks in patients with non-small cell lung cancer (NSCLC)
    Osterlind, K
    Sánchez, J
    Zatloukai, P
    Hamm, J
    Belani, C
    Kim, E
    Felip, E
    Sklenar, I
    Berton, M
    Johri, A
    [J]. LUNG CANCER, 2005, 49 : S261 - S261
  • [3] A phase I/II dose-escalation trial of patupilone (EPO906) administered every 3 weeks in patients with non-small cell lung cancer (NSCLC)
    Oesterlind, Kell
    Sanchez, Jose
    Zatloukal, Petr
    Perry, Michael
    Hamm, John
    Belani, Chandra
    Kim, Edward
    Vansteenkiste, Johan
    Felip, Enriqueta
    Berton, Myriam
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 167 - 167
  • [4] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer.
    Smit, WM
    Sufliarsky, J
    Spanik, S
    Wagnerová, M
    Kaye, S
    Oza, AM
    Gore, M
    Williams, K
    Johri, A
    Huinink, WWT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 468S - 468S
  • [5] A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC).
    Oesterlind, K
    Sanchez, JM
    Zatloukal, P
    Perry, MC
    Hamm, JT
    Belani, CP
    Kim, ES
    Vansteenkiste, JF
    Felip, E
    Berton, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 678S - 678S
  • [6] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with resistant/refractory ovarian cancer
    Smit, W. M.
    Sufliarsky, J.
    Spanik, S.
    Wagnerova, M.
    Kaye, S.
    Oza, A. M.
    Gore, M.
    Williams, K. J.
    Johri, A.
    Huinink, W. W. ten Bokkel
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 261 - 262
  • [7] Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial
    Koukourakis, MI
    Kourousis, C
    Kamilaki, M
    Koukouraki, S
    Giatromanolaki, A
    Kakolyris, S
    Kotsakis, A
    Androulakis, N
    Bahlitzanakis, N
    Georgoulias, V
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (06) : 838 - 844
  • [8] Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC):: A phase I/II trial.
    Sanchez, J. M.
    Mellemgaard, A.
    Perry, M.
    Zatloukal, P.
    Hamm, J.
    Belani, C. P.
    Kim, E.
    Felip, E.
    Berton, M.
    Johri, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 390S - 390S
  • [9] Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer
    Shepherd, FA
    Latreille, J
    Paul, K
    Eisenhauer, E
    [J]. SEMINARS IN ONCOLOGY, 1996, 23 (06) : 84 - 90
  • [10] A PHASE I / II TRIAL OF THE HDAC INHIBITOR BELINOSTAT IN COMBINATION WITH ERLOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER.
    Andersen, Jon L.
    Holm, Bente
    Rasmussen, Trine S.
    Mellemgaard, Anders
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1201 - S1202
12345